Data as of Q4 2025 (Dec 31, 2025)

BVF INC/IL

โ€ขCIK: 1056807โ€ขFiling: Q4 2025

**BVF INC/IL** manages $3.0B across a concentrated portfolio of 41 positions. The fund exhibits significant conviction in select names, with KYMR anchoring the top holdings at $428.2M. Further substantial allocations are evident in RVMD ($267.4M), MLTX ($260.3M), and GPCR ($242.0M). This structure suggests a high-conviction, deep-value approach targeting specific sector opportunities.

Total AUM
$3.0B
QoQ Performance
+20.4%
Positions
41
Top 10 Concentration
62.8%
Latest Filing
Q4 2025

Top Holdings Allocation

KYMR
RVMD
MLTX
GPCR
KYMR14.4%
RVMD9.0%
MLTX8.8%
GPCR8.1%
OLMA4.5%
MIRM4.0%
GHRS3.8%
XNCR3.7%

๐Ÿ“ˆ Biggest Buys

XNCR
XENCOR INC
+160.3%
3.7% of portfolio
IRON
DISC MEDICINE INC
NEW
1.7% of portfolio
IVVD
INVIVYD INC
NEW
1.6% of portfolio
STOK
STOKE THERAPEUTICS INC
+36.7%
2.4% of portfolio
GPCR
STRUCTURE THERAPEUTICS INC
+8.6%
8.1% of portfolio

๐Ÿ“‰ Biggest Sells

AXSM
AXSOME THERAPEUTICS INC
-90.6%
0.3% of portfolio
SEPN
SEPTERNA INC
-57.1%
1.6% of portfolio
RVMD
REVOLUTION MEDICINES INC
-15.6%
9.0% of portfolio
TYRA
TYRA BIOSCIENCES INC
-41.7%
1.9% of portfolio
PVLA
PALVELLA THERAPEUTICS INC NE
-24.3%
3.1% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

PTGX
PROTAGONIST THERAPEUTICS INC
SOLD
$170.1M
CDTX
CIDARA THERAPEUTICS INC
SOLD
$135.4M
CELC
CELCUITY INC
SOLD
$32.5M
โ€”
ESSA PHARMA INC
SOLD
$2.2M
SABS
SAB BIOTHERAPEUTICS INC
SOLD
$1.9M
+2 more exited positions

Changes from Q3 2025

NEW2 new positions
โ†‘8 increased
โ†“8 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023